Abstract
This study represents the initial step in assessing the discriminative effects of spiradoline (U62,066), a potent congener of the selective kappa-opioid agonist, U50,488. Separate groups of rats were trained to discriminate between SC injections of saline and either 3.0 mg/kg spiradoline or 3.0 mg/kg morphine in a discrete-trial shock-avoidance/escape procedure. Spiradoline-trained rats generalized completely to U50,488 (ED50s for spiradoline and U50,488 were 0.66 and 8.71 mg/kg, respectively), but selected the choice lever appropriate for saline in generalization tests with graded doses of morphine, phencyclidine, and agonist-antagonist opioids with varying degrees of kappa activity, ethylketocyclazocine, nalorphine, and butorphanol. Morphine-trained rats did not generalize to spiradoline. Naltrexone (0.01 or 0.1 mg/kg) blocked surmountably the discriminative effects of both spiradoline and morphine, but was approximately 10-fold less potent against spiradoline. These results indicate that the discriminative effects of spiradoline are mediated by kappa-opioid receptors; meaningful mu-opioid and PCP/sigma components of action were not in evidence. The potency and apparent pharmacological selectivity of spiradoline suggest the potential value of this drug for studying kappa-opioid-mediated stimulus control of behavior.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balster RL, Willetts J (1988) Receptor mediation of the discriminative stimulus properties of phencyclidine and sigma-opioid agonists. In: Colpaert FC, Balster RL (eds) Transduction mechanisms of drug stimulus. Springer, Berlin Heidelberg New York, pp 122–135
Colpaert FC, Janssen PAJ (1984) Agonist and antagonist effects of prototype opiate drugs in rats discriminating fentanyl from saline: characteristics of partial generalization. J Pharmacol Exp Ther 230:193–199
Deutsch SI, Weizman A, Goldman ME, Morihisa JM (1988) The sigma receptor: a novel site implicated in psychosis and antipsychotic drug efficacy. Clin Neuropharmacol 11:105–119
Dykstra LA, Bertalmio AJ, Woods JH (1988) Discriminative and analgesic effects of mu and kappa opioids: In vivo pA2 analysis. In: Colpaert FC, Balster RL (eds) Transduction mechanisms of drug stimuli. Springer, Berlin Heidelberg New York, pp 107–121
France CP, Woods JH (1985) Opiate agonist-antagonist interactions: application of a three-key drug discrimination procedure. J Pharmacol Exp Ther 234:81–89
Glantz SA (1988) Primer of biostatistics: the program. McGraw-Hill, New York
Hayes AG, Sheehan MJ, Tyers MB (1987) Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to μ- and κ-opioid receptor agonists. Br J Pharmacol 91:823–832
Hein DW, Young AM, Herlin S, Woods JH (1981) Pharmacological analysis of the discriminative stimulus characteristics of ethylketazocine in the rhesus monkey. J Pharmacol Exp Ther 218:7–15
Herling S, Coale EH, Valentino RJ, Hein DW, Woods JH (1980) Narcotic discrimination in pigeons. J Pharmacol Exp Ther 214:139–146
Holtzman SG (1980) Phencyclidine-like discriminative effects of opioids in the rat. J Pharmacol Exp Ther 214:614–619
Holtzman SG (1983) Discriminative stimulus properties of opioid agonists and antagonists. In: Cooper SJ (ed) Theory in psychopharmacology, vol 2. Academic Press, London, pp 1–45
Holtzman SG (1985) Discriminative stimulus properties of opioids that interact with mu, kappa and PCP/sigma receptors. In: Seiden LS, Balster RL (eds) Behavioral pharmacology: the current status. Liss, New York, pp 131–147
Holtzman SG (1986) Discriminative stimulus properties of caffeine in the rat: Noradrenergic mediation. J Pharmacol Exp Ther 239:706–714
Leander JD (1983) A kappa opioid effect: increased urination in the rat. J Pharmacol Exp Ther 244:89–94
Leslie FM (1987) Methods used for the study of opioid receptors. Pharmacol Rev 39:197–249
Locke KW, Gorney B, Cornfeldt M, Fielding S (1989) Mu-opioid component of the ethylketocyclazocine (EKC) discriminative stimulus in the rat. Psychopharmacology 99:492–496
Martin WR (1984) Pharmacology of opioids. Pharmacol Rev 35:283–323
Meecham KG, Boyle SJ, Hunter JC, Hughes J (1989) An in vitro profile of activity for the (+) and (−) enantiomers of spiradoline and PD117302. Eur J Pharmacol 173:151–157
Millan MJ (1990) κ-Opioid receptors and analgesia. TIPS 11:70–76
Picker MJ, Dykstra LA (1987) Comparison of the discriminative stimulus properties of U50,488 and morphine in pigeons. J Pharmacol Exp Ther 243:938–945
Picker MJ, Doty P, Negus SS, Mattox SR, Dykstra LA (1990) Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists. J Pharmacol Exp Ther 254:13–22
Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989) Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther 250:184–196
Schaefer GJ, Holtzman SG (1978) Discriminative effects of cyclazocine in the squirrel monkey. J Pharmacol Exp Ther 205:291–301
Schmidt WK, Rajagopolan P, Cook L, Marynowski ME, Tam SW, Johnson LC, Steinfels GF, Scribner RM, Pennev P, Mattei PL, Wuonolu MA, Johnson AL (1990) Preclinical pharmacology of DuP 747: a new potent kappa opioid analgesic. Abstr Am Chem Soc 200:59
Shannon HE (1982) Pharmacological analysis of the phencyclidine-like discriminative stimulus properties of narcotic derivatives in rats. J Pharmacol Exp Ther 222:146–151
Shannon HE, Holtzman SG (1976) Evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther 198:54–65
Shannon HE, Holtzman SG (1979) Morphine training dose: a determinant of stimulus generalization to narcotic antagonists in the rat. Psychopharmacology 61:239–244
Shearman GT, Herz A (1982a) Evidence that the discriminative stimulus properties of fentanyl and ethylketocyclazocine are mediated by an interaction with different opiate receptors. J Pharmacol Exp Ther 221:735–739
Shearman GT, Herz A (1982b) Discriminative stimulus properties of narcotic and non-narcotic drugs in rats trained to discriminate opiate kappa-receptor agonists. Psychopharmacology 78:63–66
Tang AH, Code RA (1983) Discriminative stimulus properties of nalorphine in the rhesus monkey. J Pharmacol Exp Ther 227:563–569
Ukai M, Nakayama S, Hamada T, Kameyama T (1989) Discriminative stimulus properties of the mixed agonist-antagonist pentazocine in the rat using two-choice discrete-trial avoidance paradigm. Pharmacol Biochem Behav 33:355–359
VonVoightlander PF, Lewis RA (1988) Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid. J Pharmacol Exp Ther 246:259–262
VonVoigtlander PF, Lahti RA, Ludens JH (1983) U-50488, a selective and structurally novel non-mu (kappa) opioid agonist. J Pharmacol Exp Ther 224:7–12
Young AM, Stephens KA, Hein DW, Woods JH (1984) Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J Pharmacol Exp Ther 229:118–126
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holtzman, S.G., Cook, L. & Steinfels, G.F. Discriminative stimulus effects of spiradoline, a kappa-opioid agonist. Psychopharmacology 105, 447–452 (1991). https://doi.org/10.1007/BF02244362
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244362